Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03245021
Title Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A (1stFLOR)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dr. Eliza Hawkes
Indications

follicular lymphoma

Therapies

Nivolumab + Rituximab

Nivolumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.